X0508 4 2024-07-01 0001826667 TriSalus Life Sciences, Inc. TLSI 0001982985 Desai Arjun JJ 6272 W. 91ST AVENUE WESTMINSTER CO 80031 true false false false 0 Common Stock 2024-07-01 4 A 0 74000 A 277127 D Redeemable Warrants 2024-07-01 4 D 0 246667 D 2020-12-17 Common Stock 246667 0 D As previously disclosed, on May 24, 2024, TriSalus Life Sciences, Inc. (the "Issuer"), announced the commencement of its offer (the "Issuer Tender Offer") to all holders of each class of certain outstanding warrants (the "Warrants"), consisting of (a) the Issuer's publicly-traded Warrants currently listed on the Nasdaq Global Market under the symbol "TLSIW", (b) certain Warrants issued in a private placement transaction occurring simultaneously with the closing of the initial public offering of the Issuer and (c) certain Warrants issued for working capital requirements and payment of certain expenses of the Issuer, each identified in the Prospectus/Offer to Exchange that forms a part of the Issuer's Registration Statement on Form S-4 (Registration No. 333- 279691), filed with the Securities and Exchange Commission on May 24, 2024, to receive 0.3 shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), [continued on footnote 2] [continued from footnote 1] in exchange for each Warrant tendered by the holder and exchanged pursuant to the Issuer Tender Offer. Pursuant to the Issuer Tender Offer, the Reporting Person tendered 246,667 Warrants in exchange for 74,000 shares of Common Stock. Represents Warrants received as a pro rata distribution for no consideration from MedTech Acquisition Sponsor LLC ("Sponsor") in accordance with the terms of the Sponsor's limited liability company agreement. The Warrants expire on August 9, 2028, or earlier upon redemption or liquidation. /s/ Sean Murphy, Attorney-in-Fact 2024-07-01